Cohen Investment Advisors LLC Acquires 927 Shares of Amgen Inc. (NASDAQ:AMGN)

Cohen Investment Advisors LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGNFree Report) by 9.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,273 shares of the medical research company’s stock after acquiring an additional 927 shares during the quarter. Amgen accounts for about 2.0% of Cohen Investment Advisors LLC’s investment portfolio, making the stock its 16th biggest position. Cohen Investment Advisors LLC’s holdings in Amgen were worth $3,310,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Hershey Financial Advisers LLC bought a new stake in Amgen during the second quarter worth about $30,000. nVerses Capital LLC bought a new stake in Amgen during the second quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new stake in Amgen during the second quarter worth about $33,000. FSA Wealth Management LLC lifted its position in shares of Amgen by 182.0% during the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock worth $40,000 after purchasing an additional 91 shares in the last quarter. Finally, Western Pacific Wealth Management LP lifted its position in shares of Amgen by 27.6% during the first quarter. Western Pacific Wealth Management LP now owns 162 shares of the medical research company’s stock worth $46,000 after purchasing an additional 35 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

AMGN stock traded down $2.21 during trading hours on Monday, reaching $317.45. The stock had a trading volume of 1,261,193 shares, compared to its average volume of 2,488,611. The stock has a market capitalization of $170.29 billion, a PE ratio of 45.35, a price-to-earnings-growth ratio of 2.98 and a beta of 0.61. The company has a debt-to-equity ratio of 9.64, a current ratio of 1.26 and a quick ratio of 0.89. The stock has a 50-day simple moving average of $327.28 and a 200 day simple moving average of $309.48. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85.

Amgen (NASDAQ:AMGNGet Free Report) last announced its quarterly earnings results on Tuesday, August 6th. The medical research company reported $4.97 EPS for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The firm had revenue of $8.39 billion during the quarter, compared to analyst estimates of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. The business’s revenue was up 20.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $5.00 EPS. Analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Investors of record on Friday, August 16th were issued a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.84%. The ex-dividend date was Friday, August 16th. Amgen’s payout ratio is 128.57%.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Barclays upped their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research report on Monday. Oppenheimer reiterated an “outperform” rating and set a $380.00 target price on shares of Amgen in a research report on Wednesday, August 7th. Cantor Fitzgerald assumed coverage on shares of Amgen in a research report on Friday, September 27th. They set an “overweight” rating and a $405.00 target price on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 target price on shares of Amgen in a research report on Thursday, September 26th. Finally, Robert W. Baird restated an “underperform” rating and issued a $215.00 price objective on shares of Amgen in a report on Wednesday, September 25th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $326.30.

Read Our Latest Analysis on Amgen

Amgen Profile

(Free Report)

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Recommended Stories

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.